According to Roots Analysis, the allogeneic cell therapy market is estimated to be USD 0.54 billion in 2023 and is anticipated to grow at a CAGR of 14.5% till 2035. In terms of type of therapy, stem cell therapy is anticipated to capture the highest share in allogeneic cell therapy market by 2035. Further, amongst the key geographical regions, more than 85% of the global market of allogeneic cell therapies is anticipated to be captured by players based in North America, in 2035.
Growth of allogenic cell therapy market is driven by several factors, such as rising prevalence of chronic diseases, promising development pipeline and challenges associated with autologous cell therapies.

Allogeneic Cell Therapy Market Landscape Allogenic cell therapy market landscape features the presence of close to 195 large, mid-sized and small companies developing allogeneic cell therapies for different patient segments. Notably, there are more than 480 allogeneic cell therapies that are either approved or in preclinical / clinical stage of development. Further, majority (42%) of the allogeneic cell therapies are in Phase I trials, followed by Phase I/II trials (28%) and Phase II trials (21%). In April 2023, FDA approved Gamida Cell’s umbilical cord blood-derived allogeneic stem cell therapy, Omisirge® (omidubicel-onlv), useful in the treatment of hematologic malignancies.

Rising Partnerships and Collaborations, and Funding Activity have Fueled Growth in Allogenic Cell Therapy Market Several stakeholders have forged more than 90 partnerships with other industry / non-industry players for the development of allogeneic cell therapies, in the last four years. Most of the partnerships are focused on research and development, product / technology licensing, and development and commercialization of allogenic cell therapies.

Further, close to USD 8.8 billion has been invested by several investors in this domain, since 2019. companies engaged in the development of allogeneic cell therapies. In terms of the number of funding instances, venture capital emerged as the most promising funding category.

Leading Companies in Allogeneic Cell Therapy Market Examples of key allogeneic cell therapy companies (based on number of products under development, which have also been captured in this report) include Artiva Biotherapeutics, Allogene Therapeutics, Atara Biotherapeutics, Cellenkos, Cell2Cure, Celularity, Cellular Biomedicine Group, CHABiotech, CRISPR Therapeutics, Fate Therapeutics, Fundamenta Therapeutics, GC Cell, Hope Biosciences, Immunity Bio, Mesoblast, Nanjing Bioheng Biotech, Orca Bio, Pluristem Therapeutics, Poseida Therapeutics and Stemedica Cell Technologies

All your Questions Related to Allogeneic Cell Therapy Market Answered in this Report The Allogeneic Cell Therapy Market, 2023-2035 report features an extensive study of the current market landscape, market size and future opportunities associated with the allogeneic cell therapies domain, during the given forecast period. The report answers many key questions related to this market. Click on the below link to know more about this emerging area of research. https://www.rootsanalysis.com/reports/allogeneic-cell-therapy-market.html

About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.